Javascript must be enabled to continue!
Predicting quetiapine dose in patients with depression using machine learning techniques based on real-world evidence
View through CrossRef
Abstract
Background
Being one of the most widespread, pervasive, and troublesome illnesses in the world, depression causes dysfunction in various spheres of individual and social life. Regrettably, despite obtaining evidence-based antidepressant medication, up to 70% of people are going to continue to experience troublesome symptoms. Quetiapine, as one of the most commonly prescribed antipsychotic medication worldwide, has been reported as an effective augmentation strategy to antidepressants. The right quetiapine dose and personalized quetiapine treatment are frequently challenging for clinicians. This study aimed to identify important influencing variables for quetiapine dose by maximizing the use of data from real world, and develop a predictive model of quetiapine dose through machine learning techniques to support selections for treatment regimens.
Methods
The study comprised 308 depressed patients who were medicated with quetiapine and hospitalized in the First Hospital of Hebei Medical University, from November 1, 2019, to August 31, 2022. To identify the important variables influencing the dose of quetiapine, a univariate analysis was applied. The prediction abilities of nine machine learning models (XGBoost, LightGBM, RF, GBDT, SVM, LR, ANN, DT) were compared. Algorithm with the optimal model performance was chosen to develop the prediction model.
Results
Four predictors were selected from 38 variables by the univariate analysis (p < 0.05), including quetiapine TDM value, age, mean corpuscular hemoglobin concentration, and total bile acid. Ultimately, the XGBoost algorithm was used to create a prediction model for quetiapine dose that had the greatest predictive performance (accuracy = 0.69) out of nine models. In the testing cohort (62 cases), a total of 43 cases were correctly predicted of the quetiapine dose regimen. In dose subgroup analysis, AUROC for patients with daily dose of 100 mg, 200 mg, 300 mg and 400 mg were 0.99, 0.75, 0.93 and 0.86, respectively.
Conclusions
In this work, machine learning techniques are used for the first time to estimate the dose of quetiapine for patients with depression, which is valuable for the clinical drug recommendations.
Springer Science and Business Media LLC
Title: Predicting quetiapine dose in patients with depression using machine learning techniques based on real-world evidence
Description:
Abstract
Background
Being one of the most widespread, pervasive, and troublesome illnesses in the world, depression causes dysfunction in various spheres of individual and social life.
Regrettably, despite obtaining evidence-based antidepressant medication, up to 70% of people are going to continue to experience troublesome symptoms.
Quetiapine, as one of the most commonly prescribed antipsychotic medication worldwide, has been reported as an effective augmentation strategy to antidepressants.
The right quetiapine dose and personalized quetiapine treatment are frequently challenging for clinicians.
This study aimed to identify important influencing variables for quetiapine dose by maximizing the use of data from real world, and develop a predictive model of quetiapine dose through machine learning techniques to support selections for treatment regimens.
Methods
The study comprised 308 depressed patients who were medicated with quetiapine and hospitalized in the First Hospital of Hebei Medical University, from November 1, 2019, to August 31, 2022.
To identify the important variables influencing the dose of quetiapine, a univariate analysis was applied.
The prediction abilities of nine machine learning models (XGBoost, LightGBM, RF, GBDT, SVM, LR, ANN, DT) were compared.
Algorithm with the optimal model performance was chosen to develop the prediction model.
Results
Four predictors were selected from 38 variables by the univariate analysis (p < 0.
05), including quetiapine TDM value, age, mean corpuscular hemoglobin concentration, and total bile acid.
Ultimately, the XGBoost algorithm was used to create a prediction model for quetiapine dose that had the greatest predictive performance (accuracy = 0.
69) out of nine models.
In the testing cohort (62 cases), a total of 43 cases were correctly predicted of the quetiapine dose regimen.
In dose subgroup analysis, AUROC for patients with daily dose of 100 mg, 200 mg, 300 mg and 400 mg were 0.
99, 0.
75, 0.
93 and 0.
86, respectively.
Conclusions
In this work, machine learning techniques are used for the first time to estimate the dose of quetiapine for patients with depression, which is valuable for the clinical drug recommendations.
Related Results
Corrigendum
Corrigendum
In Volume 10, Supplement 1, February 2008, this Abstract was omitted from the Poster Session. The correct citation for the Abstract is Bipolar Disord 2008; 10 (Suppl. 1). We apolog...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Quetiapine in the treatment of psychosis in Parkinson’s disease
Quetiapine in the treatment of psychosis in Parkinson’s disease
Psychosis (delusions and/or hallucinations) is a common nonmotor feature of Parkinson’s disease (PD). Use of the older ‘typical’ antipsychotic drugs led to worsening of motor sympt...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
<p dir="ltr">Background</p><p dir="ltr">Prolonged exposure to stressors without sufficient recovery can lead to physical and mental symptoms. In Sweden, individua...
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
Stress-related mental disorders : an exploration astrocytic biomarkers, comorbidities, and cognition
<p dir="ltr">Background</p><p dir="ltr">Prolonged exposure to stressors without sufficient recovery can lead to physical and mental symptoms. In Sweden, individua...
Comparison of effectiveness between Haloperidol and Quetiapine in acute manic episode
Comparison of effectiveness between Haloperidol and Quetiapine in acute manic episode
This study was conducted to compare the response rate of Quetiapine and Haloperidol in patients with acute manic episodes. A total of 120 patients with acute episode of mania with ...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...

